GlaxoSmithKline News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

11.08.25

Gepotidacin accepted for priority review by the US FDA for the oral treatment of uncomplicated urogenital gonorrhoea (EN, GlaxoSmithKline)

08.08.25

GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation (EN, GlaxoSmithKline)

29.07.25

GSK highlights new findings on Dementia and Alzheimer’s Disease at AAIC 2025, building on leadership in immunology and inflammation (EN, GlaxoSmithKline)

28.07.25

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology (EN, GlaxoSmithKline)

24.07.25

Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)

23.07.25

GSK announces extension of US Food and Drug Administration review period for Blenrep (belantamab mafodotin-blmf) in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)

17.07.25

GSK provides update on US FDA advisory committee review of Blenrep (belantamab mafodotin-blmf) combinations for patients with relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)

17.07.25

US FDA approves GSK’s Shingrix in a prefilled syringe presentation (EN, GlaxoSmithKline)

14.07.25

US FDA accepts application to review expanded use of GSK’s RSV vaccine, Arexvy, for adults 18-49 at increased risk (EN, GlaxoSmithKline)

08.07.25

ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025 (EN, GlaxoSmithKline)

07.07.25

GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) (EN, GlaxoSmithKline)

25.06.25

Price of world’s first malaria vaccine (RTS,S) for children in endemic countries to be reduced by more than half, to less than $5 (EN, GlaxoSmithKline)

23.06.25

Linerixibat accepted for review by the European Medicines Agency for cholestatic pruritus in patients with primary biliary cholangitis (PBC) (EN, GlaxoSmithKline)

20.06.25

Japan’s Ministry of Health, Labour and Welfare accepts regulatory application to expand use of GSK’s RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease (EN, GlaxoSmithKline)

13.06.25

GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older (EN, GlaxoSmithKline)

12.06.25

GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development (EN, GlaxoSmithKline)

02.06.25

Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC) (EN, GlaxoSmithKline)

29.05.25

GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio (EN, GlaxoSmithKline)

28.05.25

PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee (EN, GlaxoSmithKline)

23.05.25

Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)

19.05.25

Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)

14.05.25

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) (EN, GlaxoSmithKline)

13.05.25

GSK provides update on belrestotug development programme (EN, GlaxoSmithKline)

08.05.25

GLISTEN phase III trial results show linerixibat significantly improves cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) (EN, GlaxoSmithKline)

02.05.25

GSK continues to advance the future of respiratory medicine and patient care with new data at ATS (EN, GlaxoSmithKline)

30.04.25

Nucala (mepolizumab) delivers clinically meaningful and statistically significant reduction in COPD exacerbations, with positive MATINEE trial results published in New England Journal of Medicine (EN, GlaxoSmithKline)

30.04.25

GSK makes strong start to 2025 with growth in sales, profits and earnings (EN, GlaxoSmithKline)

17.04.25

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)

16.04.25

GSK’s 5-in-1 meningococcal vaccine Penmenvy receives positive recommendation from US Advisory Committee on Immunization Practices (EN, GlaxoSmithKline)

25.03.25

Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older (EN, GlaxoSmithKline)

25.03.25

GSK, UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to collaborate on first-of-its-kind dementia research initiative (EN, GlaxoSmithKline)

24.03.25

GSK’s application to expand use of Nucala (mepolizumab) for the treatment of COPD accepted for review by the European Medicines Agency (EN, GlaxoSmithKline)

12.03.25

ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV (EN, GlaxoSmithKline)

11.03.25

ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1 (EN, GlaxoSmithKline)

09.03.25

ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025 (EN, GlaxoSmithKline)

06.03.25

GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults (EN, GlaxoSmithKline)

03.03.25

Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP) (EN, GlaxoSmithKline)

01.03.25

Depemokimab delivers clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (EN, GlaxoSmithKline)

24.02.25

GSK plc commences share buyback programme (EN, GlaxoSmithKline)

24.02.25

GSK completes acquisition of IDRx, Inc. (EN, GlaxoSmithKline)

21.02.25

GSK announces Dr Gavin Screaton to join the Board as Non-Executive Director (EN, GlaxoSmithKline)

20.02.25

Nucala (mepolizumab) application for COPD accepted for review in China (EN, GlaxoSmithKline)

15.02.25

Penmenvy, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY (EN, GlaxoSmithKline)

05.02.25

GSK delivers strong 2024 performance with further improvement to long-term growth outlook (EN, GlaxoSmithKline)

31.01.25

European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents (EN, GlaxoSmithKline)

28.01.25

Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP (EN, GlaxoSmithKline)

27.01.25

GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research (EN, GlaxoSmithKline)

27.01.25

GSK’s Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency (EN, GlaxoSmithKline)

20.01.25

European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer (EN, GlaxoSmithKline)

13.01.25

GSK enters agreement to acquire IDRx, Inc. (EN, GlaxoSmithKline)

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	144.55	2.19 %	K V
Geberit	598.20	1.67 %	K V
Alcon	64.08	0.98 %	K V
Sonova Hldg	239.50	0.80 %	K V
Nestle	75.41	-0.63 %	K V
Zurich Insur Gr	575.40	-0.66 %	K V
UBS Group	32.10	-1.05 %	K V
Swiss Re	140.95	-1.19 %	K V
Swiss Life Hldg	834.00	-1.70 %	K V

GlaxoSmithKline Aktie VALOR 1004120 / ISIN ARDEUT110483

Nachrichten zu GlaxoSmithKline PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs

Aktien Top/Flop

Meistgelesene Nachrichten